$16.10
0[0.00%]
Last update: 4:00PM Get Real Time Here
Verona Pharma
(NASDAQ:VRNA)Verona Pharma Stock (NASDAQ:VRNA), Analyst Ratings, Price Targets, Predictions
Verona Pharma PLC has a consensus price target of $31, established from looking at the 27 latest analyst ratings. The last 3 analyst ratings were released from Piper Sandler, HC Wainwright & Co., and Wedbush on April 16, 2024, March 4, 2024, and March 1, 2024. With an average price target of $33.67 between Piper Sandler, HC Wainwright & Co., and Wedbush, there's an implied 115.67% upside for Verona Pharma PLC from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
HC Wainwright & Co.
Wedbush
Canaccord Genuity
Truist Securities
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Verona Pharma
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/16/2024 | VRNA | Buy Now | Verona Pharma | $15.61 | 130.62% | Piper Sandler | Yasmeen Rahimi | $31 → $36 | Maintains | Overweight | Get Alert |
| 03/04/2024 | VRNA | Buy Now | Verona Pharma | $15.61 | 105% | HC Wainwright & Co. | Raghuram Selvaraju | → $32 | Reiterates | Buy → Buy | Get Alert |
| 03/01/2024 | VRNA | Buy Now | Verona Pharma | $15.61 | 111.4% | Wedbush | Liana Moussatos | → $33 | Reiterates | Outperform → Outperform | Get Alert |
| 01/22/2024 | VRNA | Buy Now | Verona Pharma | $15.61 | 105% | HC Wainwright & Co. | Raghuram Selvaraju | → $32 | Reiterates | Buy → Buy | Get Alert |
| 12/29/2023 | VRNA | Buy Now | Verona Pharma | $15.61 | 105% | HC Wainwright & Co. | Raghuram Selvaraju | → $32 | Reiterates | Buy → Buy | Get Alert |
| 09/11/2023 | VRNA | Buy Now | Verona Pharma | $15.61 | 105% | HC Wainwright & Co. | Raghuram Selvaraju | → $32 | Reiterates | Buy → Buy | Get Alert |
| 09/01/2023 | VRNA | Buy Now | Verona Pharma | $15.61 | 124.22% | Canaccord Genuity | Edward Nash | → $35 | Reiterates | Buy → Buy | Get Alert |
| 08/04/2023 | VRNA | Buy Now | Verona Pharma | $15.61 | 105% | HC Wainwright & Co. | Raghuram Selvaraju | → $32 | Reiterates | Buy → Buy | Get Alert |
| 06/28/2023 | VRNA | Buy Now | Verona Pharma | $15.61 | 92.18% | Wedbush | Liana Moussatos | → $30 | Reiterates | Outperform → Outperform | Get Alert |
| 06/27/2023 | VRNA | Buy Now | Verona Pharma | $15.61 | 105% | Truist Securities | Joon Lee | → $32 | Reiterates | Buy → Buy | Get Alert |
| 06/27/2023 | VRNA | Buy Now | Verona Pharma | $15.61 | 105% | HC Wainwright & Co. | Raghuram Selvaraju | → $32 | Reiterates | Buy → Buy | Get Alert |
| 06/07/2023 | VRNA | Buy Now | Verona Pharma | $15.61 | 105% | Truist Securities | Joon Lee | $28 → $32 | Maintains | Buy | Get Alert |
| 06/02/2023 | VRNA | Buy Now | Verona Pharma | $15.61 | 105% | HC Wainwright & Co. | Raghuram Selvaraju | → $32 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2023 | VRNA | Buy Now | Verona Pharma | $15.61 | 111.4% | Canaccord Genuity | Edward Nash | $31 → $33 | Maintains | Below Average | Get Alert |
| 05/10/2023 | VRNA | Buy Now | Verona Pharma | $15.61 | 105% | HC Wainwright & Co. | Raghuram Selvaraju | — | Reiterates | → Buy | Get Alert |
| 04/10/2023 | VRNA | Buy Now | Verona Pharma | $15.61 | 105% | HC Wainwright & Co. | Raghuram Selvaraju | → $32 | Reiterates | → Buy | Get Alert |
| 03/20/2023 | VRNA | Buy Now | Verona Pharma | $15.61 | 98.59% | BTIG | Thomas Shrader | $26 → $31 | Maintains | Buy | Get Alert |
| 03/13/2023 | VRNA | Buy Now | Verona Pharma | $15.61 | 105% | HC Wainwright & Co. | Raghuram Selvaraju | → $32 | Reiterates | → Buy | Get Alert |
| 12/21/2022 | VRNA | Buy Now | Verona Pharma | $15.61 | 105% | HC Wainwright & Co. | Raghuram Selvaraju | $30 → $32 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Verona Pharma (VRNA)?
The latest price target for Verona Pharma (NASDAQ: VRNA) was reported by Piper Sandler on April 16, 2024. The analyst firm set a price target for $36.00 expecting VRNA to rise to within 12 months (a possible 123.60% upside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Verona Pharma (VRNA)?
The latest analyst rating for Verona Pharma (NASDAQ: VRNA) was provided by Piper Sandler, and Verona Pharma maintained their overweight rating.
When was the last upgrade for Verona Pharma (VRNA)?
There is no last upgrade for Verona Pharma.
When was the last downgrade for Verona Pharma (VRNA)?
There is no last downgrade for Verona Pharma.
When is the next analyst rating going to be posted or updated for Verona Pharma (VRNA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Verona Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Verona Pharma was filed on April 16, 2024 so you should expect the next rating to be made available sometime around April 16, 2025.
Is the Analyst Rating Verona Pharma (VRNA) correct?
While ratings are subjective and will change, the latest Verona Pharma (VRNA) rating was a maintained with a price target of $31.00 to $36.00. The current price Verona Pharma (VRNA) is trading at is $16.10, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.